KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Assets: 2019-2025

Historic Return on Assets for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -0.30%.

  • Esperion Therapeutics' Return on Assets fell 18.00% to -0.30% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.30%, marking a year-over-year decrease of 18.00%. This contributed to the annual value of -0.02% for FY2024, which is 93.00% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Return on Assets of -0.30% as of Q3 2025, which was up 4.83% from -0.32% recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Return on Assets ranged from a high of -0.01% in Q4 2024 and a low of -1.22% during Q3 2021.
  • Over the past 3 years, Esperion Therapeutics' median Return on Assets value was -0.32% (recorded in 2025), while the average stood at -0.49%.
  • In the last 5 years, Esperion Therapeutics' Return on Assets crashed by 87bps in 2021 and then soared by 99bps in 2024.
  • Esperion Therapeutics' Return on Assets (Quarterly) stood at -0.90% in 2021, then increased by 6bps to -0.84% in 2022, then fell by 16bps to -1.00% in 2023, then soared by 99bps to -0.01% in 2024, then dropped by 18bps to -0.30% in 2025.
  • Its Return on Assets stands at -0.30% for Q3 2025, versus -0.32% for Q2 2025 and -0.31% for Q1 2025.